Background
Phyllodes tumors (PTs) are rare fibroepithelial tumors accounting for less than 1 % of all breast neoplasms [
1,
2]. They are classified as benign, borderline and malignant [
3].
Malignant PTs account for 20 % of all PTs [
4] and may present with delayed metastases mainly in the lung [
5].
Only a few cases of PT metastatic to bone have been reported [
6]. To our knowledge, only 2 cases involving the iliac bone [
6,
7] and 1 case involving the femur [
8] are described in the literature. These papers have mainly focused on their radiological aspects. We report 2 cases of metastatic malignant PT of the breast involving the femoral head and the iliac bone and discuss the histopathological differential diagnoses.
Discussion
PT is a rare fibroepithelial tumor accounting for less than 1 % of all breast neoplasms [
1,
2]. They usually arise in women between ages 35 and 55 years and are classified as benign, borderline and malignant [
2,
3]. Malignant types present approximately 20 % of all cases [
4]. Actually, malignant PTs should be treated by conservative surgery with adequate negative surgical margins; the use of radiotherapy may be limited to patients with positive surgical margins [
9,
10]. Distant metastases are seen in 10–20 % of cases [
1]. They can occur even after technically adequate initial breast surgery [
1]. The most reliable predictive factors for development of distant metastases are stromal overgrowth, nuclear pleomorphism and high mitotic activity [
9,
11], whereas the role of tumor size and local recurrence is controversial [
1,
11,
12]. Tan et al. found, by multivariate analysis, that stromal atypia, overgrowth, surgical margins and mitoses are independently predictive of clinical behaviour [
13]. He developed a nomogram based on these criteria to predict recurrence-free survival, but the amalgamation of local with distant recurrences and the low rate of metastasis in this series could limit its ability in predicting dissemination. The recurrence free survival was 0,8 and 0,47 at 1 and 3 years for the first case, 0,76 and 0,4 at 1 and 3 years for the second case. Al-Masry et al. have shown that the expression of CD10 can be used to predict the occurrence of distant metastasis [
14].
Metastatic PTs mainly develop from 3 to 10 years after the inital therapy, but they can be delayed or occur as soon as synchronous presentation [
11]. The lung is the most common site of metastatic spread [
2,
3,
15]. Only a few cases of PT metastatic to bone have been reported [
6] with 2 cases involving the iliac bone [
6,
7] and 1 case involving the femur [
8].
Clinical features are not specific and vary among location of bone metastasis. Radiographs and computed tomography may show a solid mass adjacent to the involved bone and infiltrating the cortex and medulla in a permeative pattern [
8]. The magnetic resonance imaging may better delineate the metastatic extent [
8].
Pathological examination shows a malignant proliferation of fascicles of spindle cells with nuclear atypia and high mitotic index without epithelial component [
15,
16].
Immunohistochemistry demonstrates only vimentin positivity. Pancytokeratin, smooth muscle actin, desmin, S100 protein, CD34, C31, CD99 and CD117 are generally negative [
15,
16].
Positivity of estrogen and progesterone receptors had never been reported. These morphological and immunohistochemical findings play an important role in excluding sarcomas, myoepithelioma, metastatic sarcomatoid carcinoma, melanoma and gastrointestinal stromal tumor. Generally, it’s difficult to make a specific diagnosis only by microscopic examination, but the final diagnosis should be based on clinicopathological correlation. There is no consensus regarding adjuvant therapy. Both radiotherapy and chemotherapy are recommended in metastatic PTs [
2,
6,
16]. Ifosfamide is the most active agent [
16]; antiestrogen therapy is not indicated [
3,
16]. Some studies revealed several potentially targetable pathway including epidermal growth factor receptor, angiogenesis (vascular endothelial growth factor A, angiopoietin-2, vascular cell adhesion molecule 1, platelet- derived growth factor receptor A, pituitary tumor-transforming1) and immunotherapy (programmed cell death protein 1, programmed death-ligand 1) for patients with locally advanced or metastatic tumors [
4,
10]. Park et al. reported a major response to sunitinib and paclitaxel in a case of lung metastatic malignant PT of breast [
17].
Little is known about the prognosis of bone metastasis from malignant PT. Nguyen [
6] report one case involving the left iliac bone with good response after radiotherapy. The prognosis of malignant PT metastatic to the lung seems to be worse [
2].
Conclusion
In summary, malignant PT is a rare and aggressive fibroepithelial neoplasm. An accurate diagnosis of metastases should be based on clinicopathological correlation allowing exclusion of differential diagnoses. The goal of successful managing this tumor is early detection and complete resection prior to dissemination.
Consent
Written informed consents were obtained from the patients for publication of these Cases Report and any accompanying images. Copies of the written consents are available for review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MRE, MT, BE and MA analyzed and interpreted the patient data, drafted the manuscript and made the figures. AA, BE and MO performed the histological examination, proposed the study, supervised MRE and revised the manuscript. ZB, MI and MB have made substantial contributions to analysis and interpretation of patient data. All authors read and approved the final manuscript.